Zhongxin Jingwei, May 22, following Nanjing Chemical Fiber and Zhongtong Bus, A-share shares reappeared the "divine prophecy" of shareholders.
On the 22nd, Hanshang Group almost went up and down after the opening, but it only opened for a short time. As of press release, it was still in the state of up and down. It is worth mentioning that as early as the early morning of the 22nd, shareholders have precisely said that Hanshang Group will appear a "word board".
Source: Flush iFinD On the afternoon of 22nd, Sino Singapore Jingwei called Hanshang Group on relevant issues, but as of the time of publication, it was not connected.
According to the information on the company's official website, Hanshang Group is a listed company on the main board of Shanghai Stock Exchange integrating medicine, medical devices, assisted reproduction, health drinks, commerce and exhibition operations. It has Hanshang Big Health Company, Chengdu Dikang Pharmaceutical, Wuhan Huake Reproductive Hospital, Shangshang (Wuhan) drinks and other big health industries; The retail industry mainly includes Hanshang Ginza Shopping Center, 21st Century Shopping Center, Wuzhan Shopping Center, Wuhan Wedding Photography City; The exhibition industry has Wuhan International Convention and Exhibition Center.
In terms of performance, Hanshang Group achieved a revenue of 337 million yuan in the first quarter of 2024, down 6.88% year on year; The net profit attributable to shareholders of the listed company was 12.672 million yuan, down 47.76% year on year.
Zhongxin Jingwei noted that, benefiting from the concept of stem cells, Hanshang Group had previously harvested the limit up board on May 8 and May 9. In this regard, the company had issued an announcement that the company's production and operation activities were normal, and its daily operations had not changed significantly; At present, the company does not carry out stem cell therapy business. Wuhan Huake Reproductive Hospital, a subsidiary of the company, has been awarded the license of "Hubei Engineering Research Center for Human Stem Cell Preparation and Application and Resource Preservation". At present, it is in the early stage of research and development, and has not yet carried out clinical application. On the day after the announcement (May 10), Hanshang Group's share price immediately fell by the limit. (Zhongxin Jingwei APP)
